首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1572448

戊型肝炎診斷測試市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Hepatitis E Diagnostic Tests Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月16日 | 出版商:

Global Market Insights Inc. | 英文 127 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球戊型肝炎診斷測試市場價值約為 6,000 萬美元。戊型肝炎病毒（HEV）是戊型肝炎的罪魁禍首，由於衛生條件差和水源受污染，尤其是在發展中地區，其盛行率不斷上升。世界衛生組織 (WHO) 報告稱，全球每年發生約 2,000 萬例戊型肝炎病毒感染，導致約 330 萬有症狀病例。這種不斷上升的發生率凸顯了對可靠診斷測試的迫切需求，從而推動了市場擴張。

提高意識和全面的篩檢計劃對於推動市場成長至關重要。公共衛生措施和教育活動揭示了戊型肝炎的情況，鼓勵更多的人進行檢測。加強篩檢舉措，特別是在高風險地區，可以加強對該疾病的檢測和管理。這些努力促進早期診斷，幫助監測盛行率並遏制肝炎的傳播。

戊型肝炎診斷測試市場根據測試類型、樣本測試、最終用途和地區進行分組。

市場按測試類型分為 ELISA HEV IgM 測試、ELISA HEV IgG 測試、快速診斷測試和聚合酶鏈反應 (PCR)。到 2032 年，ELISA HEV IgM 測試部分將達到 4,470 萬美元。隨著全球對戊型肝炎的認知和篩檢的提高，特別是在高流行地區，對 ELISA HEV IgM 檢測等及時診斷工具的需求將會增加。此外，測試敏感性和特異性的進步，以及用於控制病毒性肝炎的公共衛生資金的增加，也有助於該細分市場的成長。這一趨勢強調了早期診斷和介入在管理戊型肝炎疫情、推動市場擴張方面的重要性。

根據樣本類型，戊型肝炎診斷檢測市場分為血液和糞便。 2023年，血液領域創造了5,110萬美元的收入。基於血液的診斷，包括血清學檢測和分子檢測，因其檢測 HEV 抗體和 RNA 的能力而受到高度重視。這種精確度對於診斷和監測疾病至關重要。它們的受歡迎源於它們檢測急性和慢性階段感染的能力，這對於有效管理至關重要。血液檢測具有較高的靈敏度和特異性等優點，被認為是可靠的，使其成為醫療保健專業人員的首選。因此，基於血液的部分繼續主導市場，反映出其在準確診斷戊型肝炎方面的核心作用。

在美國，戊型肝炎診斷測試市場預計到 2032 年將達到 3,420 萬美元。分子診斷和先進檢測等創新正在提高戊型肝炎檢測的準確性和速度。同時，快速和即時檢測的日益普及使得這些診斷在臨床環境中更容易實現。這項技術進步預計將透過提高診斷能力和促進更快、更有效的測試來推動市場的大幅成長。

產業生態系統分析
產業影響力
- 成長動力
  - 戊型肝炎發生率上升
  - 診斷技術的進步
  - 提高認知和篩檢計劃
- 產業陷阱與挑戰
  - 發展中地區供應有限
  - 嚴格的監管場景
成長潛力分析
監管環境
技術景觀
- 核心技術
- 鄰近技術
未來市場趨勢
差距分析
波特的分析
杵分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按測試類型，2021 - 2032 年

主要趨勢
ELISA HEV IgM 檢測
ELISA HEV IgG 測試
快速診斷測試
聚合酶鍊式反應 (PCR)

第 6 章：市場估計與預測：按樣本類型，2021 - 2032 年

主要趨勢
血
凳子

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
診斷實驗室
血庫
其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

altona Diagnostics GmbH
CTK Biotech, Inc.
Dia.Pro Diagnostic Bioprobes s.r.l
DiaSorin S.p.A.
ELITechGroup ( Bruker company)
F. Hoffmann-La Roche Ltd
Fortress Diagnostics
Genscript Biotech Corporation
Guangzhou Wondfo Biotech Co., Ltd.
Medsource Ozone Biomedicals Pvt. Ltd.
MIKROGEN GmbH
MP Biomedicals
Primer Design
Wantai BioPharm

簡介目錄

Product Code: 10834

The Global Hepatitis E Diagnostic Tests Market was valued at approximately USD 60 million in 2023. Projections indicate a growth rate of 4.3% CAGR from 2024 to 2032. The global surge in hepatitis E cases has increased the demand for efficient diagnostic solutions. The hepatitis E virus (HEV) is the culprit behind hepatitis E, with its prevalence rising due to poor sanitation and tainted water sources, notably in developing areas. The World Health Organization (WHO) reports that around 20 million global infections of the hepatitis E virus occur annually, leading to roughly 3.3 million symptomatic cases. This rising incidence highlights the urgent need for dependable diagnostic tests, driving market expansion.

Heightened awareness and comprehensive screening programs are pivotal in driving market growth. Public health initiatives and educational campaigns have shed light on hepatitis E, encouraging more individuals to pursue testing. Enhanced screening initiatives, especially in high-risk regions, bolster the detection and management of the disease. These efforts promote early diagnosis and help monitor prevalence and curb the spread of hepatitis.

The Hepatitis E Diagnostic Tests Market is grouped based on test type, sample test, end-use, and region.

The market is segmented by test type into ELISA HEV IgM test, ELISA HEV IgG test, rapid diagnostics test, and polymerase chain reaction (PCR). The ELISA HEV IgM test segment will reach USD 44.7 million by 2032. The test is significant because it identifies recent HEV infections by detecting IgM antibodies, which appear shortly after infection onset. As global awareness and screening for hepatitis E increase, especially in high-prevalence regions, the demand for timely diagnostic tools like the ELISA HEV IgM test will rise. Additionally, advancements in test sensitivity and specificity, along with increased public health funding for viral hepatitis control, contribute to this segment's growth. This trend underscores the importance of early diagnosis and intervention in managing hepatitis E outbreaks, driving market expansion.

Based on sample type, the hepatitis E diagnostic tests market is divided into blood and stool. In 2023, the blood segment generated USD 51.1 million. Blood-based diagnostics, including serological assays and molecular tests, are highly valued for their ability to detect HEV antibodies and RNA. This precision is crucial for diagnosing and monitoring the disease. Their popularity stems from their ability to detect infections in both acute and chronic stages, which is essential for effective management. With advantages like higher sensitivity and specificity, blood tests are considered reliable, making them the preferred choice among healthcare professionals. Consequently, the blood-based segment continues to dominate the market, reflecting its central role in accurately diagnosing hepatitis E.

In the U.S., the hepatitis E diagnostic tests market is projected to reach USD 34.2 million by 2032. Key drivers include technological advancements in diagnostics and the rise of point-of-care testing. Innovations such as molecular diagnostics and advanced assays are enhancing the accuracy and speed of hepatitis E detection. At the same time, the growing availability of rapid and point-of-care tests is making these diagnostics more accessible in clinical settings. This technological progress is expected to drive substantial market growth by improving diagnostic capabilities and facilitating quicker, more efficient testing.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising hepatitis E incidence
  - 3.2.1.2 Advancement in diagnostic technologies
  - 3.2.1.3 Rising awareness and screening programs
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Limited availability in developing regions
  - 3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Gap analysis
3.8 Porter's analysis
3.9 PESTLE analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 ELISA HEV IgM test
5.3 ELISA HEV IgG test
5.4 Rapid diagnostics test
5.5 Polymerase chain reaction (PCR)

Chapter 6 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Blood
6.3 Stool

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Blood banks
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa